This bridging study ( JMIL ) further evaluated the efficacy and safety of first-line pemetrexed/cisplatin ( PC ) versus gemcitabine/cisplatin ( GC ) in Chinese patients with nonsquamous non-small cell lung cancer ( NSCLC ) .